Chronic liver disease
chronic disease
non-alcoholic fatty liver disease
pathogenesis of fatty liver disease
treatment of liver cirrhosis
Treatment of fatty liver
animal models of liver disease
early cirrhosis
progression of cirrhosis
chronic non-communicable disease
patients
effects of bacterial translocation
modulation of bacterial translocation
novel nanoporous carbon
bacterial resistance
recurrent complications of advanced cirrhosis
innovative therapy
alcohol use
current state-of-the-art therapy
cheap nanoporous carbon
novel strategy
cost
long-term antibiotic therapy
continued development
European obesity
European population
clinical trials
economic burden
economic productivity
Clinical evaluation of carbons
problems
viral hepatitis
controlled porosity
infection
absorbed antibiotics
central factors
resistant organisms
Gut-derived endotoxins
management
public sector investment
CARBALIVE project
alarming rate
enhanced quality of life
survival
prevention
ageing
efficacy
results
deaths
validation
academic-industrial consortium
TRL
safety
main causes
Europeans accounting
unmet need
feasibility studies
Exploitation